PE20221280A1 - Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos - Google Patents

Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Info

Publication number
PE20221280A1
PE20221280A1 PE2022000972A PE2022000972A PE20221280A1 PE 20221280 A1 PE20221280 A1 PE 20221280A1 PE 2022000972 A PE2022000972 A PE 2022000972A PE 2022000972 A PE2022000972 A PE 2022000972A PE 20221280 A1 PE20221280 A1 PE 20221280A1
Authority
PE
Peru
Prior art keywords
ion channel
compound
preparation
methods
modulators
Prior art date
Application number
PE2022000972A
Other languages
English (en)
Inventor
Botella Gabriel Martinez
Walter J Lunsmann
Sapna Makhija Garad
David Reed
Andrew Mark Griffin
Michael Kristopher Mathieu Kahlig
Brian Edward Marron
Carlos Loya
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of PE20221280A1 publication Critical patent/PE20221280A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Referida a una forma de dosificacion que comprende de 0,1 mg a 500 mg del Compuesto 1 y un excipiente farmaceuticamente aceptable, donde el compuesto 1. El compuesto 1 puede estar en forma cristalina. Tambien esta referida a un metodo de preparacion del compuesto 1. Dichas composiciones o formas de dosificacion que comprenden al compuesto 1 son utiles en el tratamiento de enfermedades relacionadas con la funcion anomala de un canal de ion sodio que incluye trastornos neurologicos tales como sindrome de Dravet o epilepsia, entre otros.
PE2022000972A 2019-11-27 2020-11-25 Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos PE20221280A1 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962941322P 2019-11-27 2019-11-27
US201962941319P 2019-11-27 2019-11-27
US202063001801P 2020-03-30 2020-03-30
US202063001906P 2020-03-30 2020-03-30
US202063028229P 2020-05-21 2020-05-21
US202063082864P 2020-09-24 2020-09-24
US202063082857P 2020-09-24 2020-09-24
PCT/US2020/062317 WO2021108625A1 (en) 2019-11-27 2020-11-25 Formulations of ion channel modulators and methods of preparation and use of ion channel modulators

Publications (1)

Publication Number Publication Date
PE20221280A1 true PE20221280A1 (es) 2022-09-05

Family

ID=76130400

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000972A PE20221280A1 (es) 2019-11-27 2020-11-25 Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Country Status (16)

Country Link
US (1) US20230348466A1 (es)
EP (1) EP4065114A4 (es)
JP (1) JP2023504038A (es)
KR (1) KR20220121238A (es)
CN (1) CN115038442A (es)
AU (1) AU2020392128A1 (es)
BR (1) BR112022010329A2 (es)
CA (1) CA3163091A1 (es)
CL (1) CL2022001384A1 (es)
CO (1) CO2022008769A2 (es)
EC (1) ECSP22049650A (es)
IL (1) IL293264A (es)
MX (1) MX2022006452A (es)
PE (1) PE20221280A1 (es)
SA (1) SA522432737B1 (es)
WO (1) WO2021108625A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116763791A (zh) 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
BR112022010186A2 (pt) * 2019-11-26 2022-08-09 Praxis Prec Medicines Inc Moduladores de canal iônico
WO2021108625A1 (en) * 2019-11-27 2021-06-03 Praxis Precision Medicines, Inc. Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
GB2597320A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
CN116763791A (zh) 2016-11-28 2023-09-19 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
CN117756800A (zh) 2018-05-30 2024-03-26 普拉克西斯精密药物股份有限公司 离子通道调节剂
WO2021108625A1 (en) * 2019-11-27 2021-06-03 Praxis Precision Medicines, Inc. Formulations of ion channel modulators and methods of preparation and use of ion channel modulators
WO2023211852A1 (en) * 2022-04-26 2023-11-02 Praxis Precision Medicines, Inc. Treatment of neurological disorders

Also Published As

Publication number Publication date
ECSP22049650A (es) 2022-07-29
KR20220121238A (ko) 2022-08-31
CO2022008769A2 (es) 2022-07-19
CL2022001384A1 (es) 2023-03-10
EP4065114A4 (en) 2023-12-20
CA3163091A1 (en) 2021-06-03
IL293264A (en) 2022-07-01
JP2023504038A (ja) 2023-02-01
US20230348466A1 (en) 2023-11-02
WO2021108625A1 (en) 2021-06-03
EP4065114A1 (en) 2022-10-05
SA522432737B1 (ar) 2024-01-03
CN115038442A (zh) 2022-09-09
MX2022006452A (es) 2022-07-11
AU2020392128A1 (en) 2022-06-09
BR112022010329A2 (pt) 2022-08-16

Similar Documents

Publication Publication Date Title
PE20221280A1 (es) Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
BR112022010349A2 (pt) Compostos bifuncionais para degradar btk por meio de via da ubiquitina-proteossoma
ECSP14013324A (es) Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
MX2022014313A (es) Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada.
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CL2016001874A1 (es) Forma de dosificación oral sólida de liberación modificada que comprende pridopidina y un excipiente de control de velocidad; formulación farmacéutica que comprende a la forma de dosificación; uso de la forma de dosificación o de la formulación farmacéutica para tratar una enfermedad neurodegenerativa o relacionada con dopamina, como la enfermedad de huntington, entre otras.
CR20210201A (es) Nuevos compuestos antihelmínticos
PH12020550341A1 (en) Niraparib formulations
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
CL2011000148A1 (es) Compuestos derivados de piperidina puenteada tipo quinoxalina, de accion moduladora del receptor orl-1; composicion farmaceutica que los comrende; procedimiento de preparacion de la composicion; kit farmaceutico; y uso de los compuestos para el tratamiento del dolor.
GT201200024A (es) Formulación subcutánea de anticuerpo anti-her2
AR045630A1 (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
AR070025A1 (es) Uso de derivados de 1-amino-alquilciclohexano para el tratamiento del tinnitus coclear y composicion farmaceutica
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
CO2022017622A2 (es) Inhibidores de quinasa nek7
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
ECSP099596A (es) Composición farmacéutica que contiene una combinación de tramadol y ketoprofeno
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
AR036009A1 (es) Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica